BioNTech SE (BNTX) Gets a Hold Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on BioNTech SE (BNTXResearch Report) today and set a price target of $183.00. The company’s shares closed last Monday at $140.32, close to its 52-week low of $121.32.

According to, Kasimov is a 5-star analyst with an average return of 18.2% and a 54.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Allogene Therapeutics.

Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $251.89, an 80.5% upside from current levels. In a report released today, Jefferies also maintained a Hold rating on the stock with a $230.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on BioNTech SE’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.53 billion and net profit of $3.17 billion. In comparison, last year the company earned revenue of $345 million and had a net profit of $367 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More